Xianming Cai

Xianming Cai

Auto-generated profile, based on publicly available information

Xianming Cai

Department of Epidemiology and Biostatistics, Peking University, School of Public Health, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Journal of Global Health
Verified
Journal Article
Open access
QXQingsong Xu
Qingsong Xu
XZXiyu Zhang
Xiyu Zhang
TZTianshuo Zhao
Tianshuo Zhao
XCXianming Cai
Xianming Cai
SZSihui Zhang
Sihui Zhang
FCFuqiang Cui
Fuqiang Cui
Sexually transmitted infection (STI) is an infection caused by a pathogen through sexual contact, and develops into sexually transmitted disease when a recognisable disease state occurs [1]. STIs cause acute urogenital conditions such as cervicitis, urethritis, vaginitis, and genital ulceration [2]. Since the 1990s, the global spread of STIs has significantly decreased, mainly thanks to […]

11 October 2023 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
MLMing Liu
Ming Liu
TZTianshuo Zhao
Tianshuo Zhao
QMQiuyue Mu
Qiuyue Mu
RZRuizhi Zhang
Ruizhi Zhang
CLChunting Liu
Chunting Liu
FCFuqiang Cui
Fuqiang Cui
Background: As the SARS-CoV-2 attenuates and antibodies from the COVID-19 vaccine decline, long-term attention should be paid to the durability of primary booster administration and the preventive effect of the second or multiple booster doses of the COVID-19 vaccine. Objective: This study aimed to explore the durability of primary booster administration and the preventive effect of second or multiple booster doses of the COVID-19 vaccine. Methods: We established a bidirectional cohort in Guizhou Province, China. Eligible participants who had received the primary booster dose were enrolled for blood sample collection and administration of the second booster dose. A retrospective cohort for the time of administration was constructed to evaluate antibody attenuation 6-12 months after the primary booster dose, while a prospective cohort on the vaccine effect of the second booster dose was constructed for 4 months after the second administration. Results: Between September 21, 2022, and January 30, 2023, a total of 327 participants were included in the final statistical analysis plan. The retrospective cohort revealed that approximately 6-12 months after receiving the primary booster, immunoglobulin G (IgG) slowly declined with time, while immunoglobulin A (IgA) remained almost constant. The prospective cohort showed that 28 days after receiving the second booster, the antibody levels were significantly improved. Higher levels of IgG and IgA were associated with better protection against COVID-19 infection for vaccine recipients. Regarding the protection of antibody levels against post–COVID-19 symptoms, the increase of the IgG had a protective effect on brain fog and sleep quality, while IgA had a protective effect on shortness of breath, brain fog, impaired coordination, and physical pain. Conclusions: The IgG and IgA produced by the second booster dose of COVID-19 vaccines can protect against SARS-CoV-2 infection and may alleviate some post–COVID-19 symptoms. Further data and studies on secondary booster administration are required to confirm these conclusions.

14 March 2023 in JMIR Preprints
Verified
Preprint
Open access
MLMing Liu
Ming Liu
TZTianshuo Zhao
Tianshuo Zhao
QMQiuyue Mu
Qiuyue Mu
RZRuizhi Zhang
Ruizhi Zhang
CLChunting Liu
Chunting Liu
FCFuqiang Cui
Fuqiang Cui
BACKGROUND As the SARS-CoV-2 attenuates and antibodies from the COVID-19 vaccine decline, long-term attention should be paid to the durability of primary booster administration and the preventive effect of the second or multiple booster doses of the COVID-19 vaccine. OBJECTIVE This study aimed to explore the durability of primary booster administration and the preventive effect of second or multiple booster doses of the COVID-19 vaccine. METHODS We established a bidirectional cohort in Guizhou Province, China. Eligible participants who had received the primary booster dose were enrolled for blood sample collection and administration of the second booster dose. A retrospective cohort for the time of administration was constructed to evaluate antibody attenuation 6-12 months after the primary booster dose, while a prospective cohort on the vaccine effect of the second booster dose was constructed for 4 months after the second administration. RESULTS Between September 21, 2022, and January 30, 2023, a total of 327 participants were included in the final statistical analysis plan. The retrospective cohort revealed that approximately 6-12 months after receiving the primary booster, immunoglobulin G (IgG) slowly declined with time, while immunoglobulin A (IgA) remained almost constant. The prospective cohort showed that 28 days after receiving the second booster, the antibody levels were significantly improved. Higher levels of IgG and IgA were associated with better protection against COVID-19 infection for vaccine recipients. Regarding the protection of antibody levels against post–COVID-19 symptoms, the increase of the IgG had a protective effect on brain fog and sleep quality, while IgA had a protective effect on shortness of breath, brain fog, impaired coordination, and physical pain. CONCLUSIONS The IgG and IgA produced by the second booster dose of COVID-19 vaccines can protect against SARS-CoV-2 infection and may alleviate some post–COVID-19 symptoms. Further data and studies on secondary booster administration are required to confirm these conclusions.